Brazilian journal of anesthesiology (Elsevier)最新文献

Background: Percutaneous Nephrolithotomy (PCNL) is a well-established surgical procedure for removal of large, multiple, and complex renal calculi in children. Combining loco-regional techniques with general anesthesia has gained increasing popularity in pediatric anesthesia. The objective of this trial was to evaluate the efficacy of Erector Spinae Plane Block (ESPB) versus thoracic Paravertebral Block (PVB) in pediatric patients undergoing PCNL procedure.

Methods: Fifty-six children, aged 2‒7 years, who underwent PCNL procedure under general anesthesia were randomly assigned to receive either ESPB (n = 28) or thoracic PVB (n = 28) with the same anesthetic mixture of 0.3 mL.kg^-1 bupivacaine 0.25% in epinephrine 1:100000. The primary outcome was time to first rescue analgesia (nalbuphine).

Results: The time to first rescue analgesia was 15.98 ± 10.17 hours (95% CI: 12.14-19.82) in the ESPB group versus 18.18 ± 9.18 hours (95% CI: 14.7-21.58) in the thoracic PVB group with no significant difference (p = 0.464, log-rank test). Moreover, the total dose and frequency of administration of nalbuphine during the first 24 postoperative hours were comparable between the two studied groups (p = 0.488 and 0.479 respectively). However, the time to conduct the block was significantly shorter in the ESPB group versus the thoracic PVB group (4.37 ± 1.08 minutes vs. 5.05 ± 1.17 minutes respectively, p = 0.028).

Conclusion: ESPB was not found to be more effective than thoracic PVB for postoperative pain management in children undergoing PCNL procedure. Moreover, intraoperative hemodynamics and maximum sevoflurane concentration were comparable. The time to conduct ESPB was significantly shorter; hence, it could be considered as an easy alternative to thoracic PVB for this procedure.

Introduction: Intracranial pressure can increase during video-laparoscopic prostatectomy due to the Trendelenburg position and pneumoperitoneum, potentially leading to complications. The Optic Nerve Sheath Diameter (ONSD) has emerged as a reliable, non-invasive method to assess ICP. Mannitol is commonly used to reduce ICP, but its intraoperative effects in this surgical setting remain unclear. This study aimed to evaluate the impact of mannitol administration on ICP, as assessed by ONSD.

Methods: This single-center, randomized, parallel-group, non-blinded clinical trial, 1:1 allocation, included 48 patients undergoing video-laparoscopic prostatectomy at a tertiary hospital in Brazil. Participants were randomly assigned to either the Mannitol Group, receiving 0.5 g.kg^-1 of intravenous mannitol after 120 minutes in Trendelenburg, or the Control Group, which did not receive mannitol. ONSD was measured using ultrasonography at four intraoperative time points (T1-T4). Additional variables analyzed included hemodynamic and respiratory parameters, surgery duration, and extubation time. Statistical analysis was conducted using a linear mixed-effects model.

Results: ONSD increased in both groups between T1 and T3, followed by a reduction at T4. However, the decrease in ONSD in the Mannitol Group was not statistically significant compared to the Control Group. Regarding extubation, the mean extubation time was 24.04 ± 15.71 minutes in the Mannitol Group and 22.79 ± 15.37 minutes in the Control Group (p = 0.782).

Conclusion: Mannitol administration during video-laparoscopic prostatectomy did not result in significant differences in ONSD trajectory or extubation time compared with the control group. At the dose and timing used, mannitol did not modify intraoperative surrogate measures of intracranial pressure.

Background: Remimazolam, a short-acting benzodiazepine, has emerged as a potential safer alternative for sedation in Flexible Bronchoscopy (FB). This meta-analysis compares its efficacy and safety with Propofol, Dexmedetomidine, and Midazolam in adult patients undergoing FB.

Methods: PubMed, Embase, and Cochrane databases were searched on July 17, 2025, for trials comparing Remimazolam with other sedatives. Primary outcomes included hypotension, bradycardia, and intraprocedural opioid consumption; secondary outcomes were hypoxia, respiratory depression, patient satisfaction, induction time, and recovery time. Pooled Risk Ratios (RR), Mean Differences (MD), and Standardized Mean Differences (SMD) were calculated using a random-effects model in R (4.4.0). Risk of bias was assessed using the RoB2 tool, and subgroup analyses were conducted for each comparator.

Results: Eleven trials (1,884 patients) were included. Remimazolam reduced respiratory depression (RR = 0.44 [95% CI 0.29; 0.67]; p = 0.0002; I² = 0%), hypoxia incidence (RR = 0.60 [95% CI 0.39; 0.93]; p = 0.0227; I² = 64.7%), bradycardia (RR = 0.39 [95% CI 0.20; 0.77]; p = 0.0069; I² = 52.3%), and hypotension (RR = 0.61 [95% CI 0.40; 0.95]; p = 0.0289; I² = 74.0%) compared to all sedatives. Compared to Propofol, Remimazolam reduced the incidence of hypotension (RR = 0.42 [95% CI 0.31; 0.58]; p < 0.0001; I² = 0%), respiratory depression (RR = 0.41 [95% CI 0.25; 0.68]; p = 0.0005; I² = 12.3%), but increased induction time (MD = 0.61 min [95% CI 0.23; 0.99]; p = 0.002; I² = 90.9%). Compared to Dexmedetomidine, it improved satisfaction (SMD = 0.23 [95% CI 0.07; 0.39]; p = 0.004; I² = 0%) and reduced recovery time (MD = -1.79 min [95% CI -2.66; -0.92]; p < 0.001; I² = 90.7%), hypoxia incidence (RR = 0.49 [95% CI 0.28; 0.88]; p = 0.0162; I² = 60.3%), and induction time (MD = -2.21 min [95% CI -2.41; -2.00]; p < 0.001; I² = 0%). Compared to Midazolam, Remimazolam increased sedation success (RR = 2.03 [95% CI 1.40; 2.95]; p = 0.0002; I² = 50%), shortened induction time (MD = -0.69 min [95% CI -1.37; -0.01]; p = 0.047; I² = 81.5%), and recovery time (MD = -4.49 min [95% CI -7.06; -1.92]; p < 0.001; I² = 40.9%).

Conclusions: Remimazolam reduced respiratory depression overall and demonstrated improved safety, faster recovery, and greater efficacy compared to Propofol, Dexmedetomidine, and Midazolam, respectively, supporting its potential as an effective alternative for sedation in FB. Nonetheless, substantial heterogeneity in certain outcomes and the relatively small sample size in some comparisons limit the generalizability of our findings.

Systematic review protocol: PROSPERO (CRD 42024568148).

Background: Pulmonary aspiration during anesthesia, though rare, can be catastrophic. Gastric ultrasound provides an objective assessment of gastric contents and may be particularly relevant for children with Cerebral Palsy (CP), who are at risk of delayed gastric emptying.

Methods: We conducted a cross-sectional study in a pediatric hospital including children scheduled for elective surgery per ASA fasting guidelines. Preoperative gastric ultrasound measured antral CSA in right lateral decubitus, and gastric volume was estimated using the Perlas formula. Fasting time, medication use, and clinical data were recorded. Group comparisons used Wilcoxon, Fisher's exact, or Chi-Square tests; multiple linear regression adjusted for confounders.

Results: Sixty-two children were studied: 30 with Cerebral Palsy (CP) and 32 controls. No patient exceeded the high-risk gastric volume threshold (1.5 mL.kg^-1) and no surgeries were cancelled. CP patients had shorter fasting times (6.5 vs. 8.0h; p < 0.001) and higher medication use (47% vs. 6.3%; p < 0.001). Gastric CSA (4.0 vs. 3.0 cm²; p < 0.001) and estimated gastric volume.kg^-1 (0.7 vs. 0.4 mL.kg^-1; p < 0.001) were greater in CP. Multivariable models showed attenuation, but quantile regression confirmed higher lower CSA (+1.25 cm²; p = 0.007). Excluding medication users, CP remained associated with greater gastric volume.

Conclusions: Children with cerebral palsy exhibit larger CSA and higher gastric volumes despite adequate fasting. Although clinically safe, these findings support the role of gastric ultrasound in preoperative risk assessment for this vulnerable group.

Background: Coronary Artery Bypass Grafting (CABG) is the most widely used cardiac intervention and can be accomplished without an extracorporeal circulation off-pump. The benefits of antifibrinolytics in off-pump CABG have yet to be demonstrated.

Methods: Randomized Controlled Trials (RCTs) and observational studies comparing the use of antifibrinolytic agents (tranexamic acid, aprotinin, and epsilon-aminocaproic) versus controls in patients undergoing off-pump CABG were searched in the PubMed, Embase, and Cochrane databases. Outcomes included thromboembolic events, in-hospital mortality, overall mortality, bleeding, Intensive Care Unit (ICU) length of stay, and blood product transfusions. Meta-analyses were conducted using the Inverse Variance method under a random-effects model, with p < 0.05 considered statistically significant.

Results: Of the 23,149 patients in 20 RCTs and seven observational studies, 51% received antifibrinolytic agents (tranexamic acid or aprotinin). Observational and randomized designs were analyzed separately in primary subgroup analyses. Significant reduction was found for overall mortality (RR = 0.72; [95% CI 0.54-0.95]) in the RCT subgroup. Red-blood-cell transfusion requirements were reduced (RR = 0.65; [95% CI 0.53, 0.78]) as well as Platelets (RR = 0.59; [95% CI 0.41, 0.84]) and fresh-frozen-plasma (RR = 0.39; [95% CI 0.36, 0.42]) transfusion requirement. The RCT subgroup showed a reduction in thromboembolic events (RR = 0.55; [95% CI 0.39, 0.79]).

Conclusions: In off-pump CABG, antifibrinolytics reduced the need for blood transfusion while reducing thromboembolic events and overall mortality in RCT subgroups, while pooled analyses combining RCTs and observational studies did not demonstrate significant reductions. PROSPERO LINK: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024545640.

Background: Post-spinal back pain is suggested to occur as a result of a localized inflammatory response that is often associated with some degree of muscle spasm. We aimed to evaluate the effect of platelet-rich plasma (PRP) in reducing the incidence of post-spinal back pain.

Methods: One hundred patients were randomly enrolled and scheduled for elective gynecological surgery under spinal anesthesia. After the subarachnoid block, group A (placebo) received 2 mL of sodium chloride 0.9% injected into the track of spinal needle during its withdrawal (2 mm after outward withdrawal in muscles and subcutaneous tissues). While patients in group B (PRP); received 2 ml of PRP injected into the track of the spinal needle during its withdrawal. The primary outcome was the number of patients who developed post-spinal low back pain within the first week following the subarachnoid block. Secondary outcomes included the time of the first analgesic request and total meperidine consumption during the first 24 h postoperatively.

Results: Fifteen patients in the PRP group developed low back pain during the first week following subarachnoid block compared to 26 patients in the placebo group (p = 0.037). There was a significant decrease in the mean meperidine consumption during first 24 h postoperatively in PRP group (174 ± 14 mg) compared to placebo group (210 ± 22 mg) (p < 0.0001). Also, the first analgesic request was significantly delayed in PRP group (243 ± 21 min.) compared to placebo group (185 ± 31 min.) (p < 0.0001).

Conclusion: This study demonstrated the positive effects of platelet-rich plasma on the prevention of post-spinal backache.

This article has been withdrawn at the request of the editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.